



## **PRELIMINARY 2025 CONSOLIDATED REPORT**

**Board of Administrators of  
Farmaceutica REMEDIA S.A.**

### **Farmaceutica REMEDIA S.A.**

Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197

Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640  
remedia@remedia.ro, www.remedia.ro

Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082

IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest

IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

**PRELIMINARY 2025 CONSOLIDATED REPORT**  
**According to F.S.A. Regulation No. 5/2018**

Date of the report: 25.02.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**  
Paid-up share capital: **9.548.082 Lei**  
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd., pc  
330160**  
Tel./fax.: **+40 254 223 260, +40 254 226 197**  
No. and date of registration  
with the Trade Register Office: **J20/700/25.07.1991**  
Tax registration number: **RO2115198**

Securities: **RMAH shares**  
**(Registration certificate No. AC-1470-7/17.06.2021)**  
Type: **Common Nominative**  
Date of registration: **17.03.1997**  
Nominal value: **0,10 Lei**  
Position in RNSC Register: **1636**  
Total number: **95.480.820**  
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010,70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	<b>TOTAL</b>	<b>95.480.820</b>	<b>9.548.082,00 Lei</b>

Organised market on which securities are traded:

**Bucharest Stock Exchange – Standard category**

The total market value on 25.02.2026 is of 85.932.738 Lei, at a value of a 0,90 Lei/RMAH share

## 1. Important events to report

In **January 2025**, Farmaceutica REMEDIA acquired 24% of the share capital of Novoengrama SRL, a medical recovery company operating in Cluj Napoca.

In **April 2025**, Farmaceutica REMEDIA Distribution & Logistics SRL (FRDL) closed its logistics warehouse in Pitești as a measure to streamline its operating costs.

In **September 2025**, Farmaceutica REMEDIA completed a share buyback operation carried out with the aim of implementing a Stock Option Plan. The number of shares repurchased on 23.09.2025, as part of the Public Tender Offer approved by the ASF through Decision 841/28.08.2025 and Amendment 888/11.09.2025, is 954. 808 shares, representing 1% of the share capital. The total amount paid by Farmaceutica REMEDIA was 811,586.80 Lei, with a repurchase price of 0.85 Lei per share.

In **November 2025**, in order to streamline operating costs in the pharmacy business line, transferred in 2024 to Farmaceutica REMEDIA Distribution & Logistics SRL, the rural pharmacies in Mohu (Sibiu County) and Toplița (Hunedoara County) and Drogheria Horea in Deva were closed.

## 2. The general description of the financial position and of the issuer's performances and of its branches related to 2025

During 01.01.2025 – 31.12.2025, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2025 (Lei)	Realisations Jan-Dec 2024 (Lei)	Evolution 2025/2024 (%)
1.	Net sales of goods *	752.452.265	737.609.125	2,01%
2.	Other operating revenues	10.753.394	9.407.028	14,31%
3.	Total operating income	763.205.659	747.016.152	2,17%
4.	Total operational costs *	748.336.052	733.918.239	1,96%
5.	Operating result	14.869.606	13.097.914	13,53%
6.	Financial result	1.476.144	996.356	48,15%
7.	Gross result	16.345.750	14.094.270	15,97%

\* Including trade discounts granted/received

A breakdown of sales of goods by segments of activity is presented as follows:  
Lei

REMEDIA Pharmacies	10.270.578	1,4%
Distribution	500.474.842	66,5%
Hospitals & Clinics Distribution	234.904.016	31,1%
BD Rowa	6.802.827	1%
<b>Total</b>	<b>752.452.263</b>	<b>100 %</b>

"Other operating revenues" mainly comprise the following categories of revenues:

- rents
- services (logistics, registration, marketing)
- BD Rowa services
- sale of assets

- other services
- real estate investments
- other operating revenue

**3. The preliminary financial statements as of 31.12.2025 were not audited by the independent financial auditor.**

**4. Economic-Financial Indicators as of 31.12.2025**

<b>LIQUIDITY AND WORKING CAPITAL</b>	<b>FR</b>	<b>FRDL</b>
<b>Current liquidity (Current assets / Current debts)</b>	6,77	1,06
Current assets	21.287.846	312.279.811
Current debts	3.146.744	295.937.164
<b>Degree of indebtedness (Borrowed capital / Equity x 100)</b>	<b>0,00%</b>	<b>0,00%</b>
Borrowed capital	0	0
Equity	59.998.974	21.632.780
<b>Turnover speed for client debit items (Average customer balance /turnover *365)</b>	<b>88 days</b>	<b>97 days</b>
Average customer balance	3.570.517	199.860.554
Net turnover	14.843.465	749.889.588
<b>Turnover speed of stocks (average stock/ net COGS)*365</b>	<b>71 days</b>	<b>30 days</b>
Average stock	1.414.583	56.676.624
COGS net	7.283.491	691.245.167

**Notes:**

<sup>1)</sup> **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

<sup>2)</sup> **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of these companies there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

<sup>3)</sup> **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances.

<sup>4)</sup> The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators  
 "TARUS" Valentin Norbert TARUS e.U.

by representative  
 Valentin-Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

	31.12.2025	31.12.2024
<b>Net turnover</b>	<b>759.757.573</b>	<b>743.790.879</b>
Income from the sale of goods	755.209.787	740.088.891
Commercial discounts granted	-2.757.522	-2.479.766
Income from services provided and rents	7.305.308	6.181.754
<b>Other operating income</b>	<b>3.448.086</b>	<b>3.225.274</b>
<b>OPERATING INCOME - TOTAL</b>	<b>763.205.659</b>	<b>747.016.152</b>
<b>Expenses with materials</b>	<b>699.229.099</b>	<b>685.783.592</b>
Expenses regarding goods	717.809.423	702.578.840
Commercial discounts received	-21.176.504	-19.355.150
Expenses with raw materials and consumables	1.536.832	1.649.227
Other expenses with materials (inventory objects)	129.860	135.962
Energy and water expenses	929.488	774.712
<b>Expenses with personnel</b>	<b>25.157.758</b>	<b>25.363.854</b>
Salaries and allowances	21.626.025	20.574.326
Expenses with insurance and social protection	1.152.230	1.142.746
Other personnel expenses	2.379.503	3.646.782
<b>Amortisations and provisions</b>	<b>1.579.038</b>	<b>3.282.862</b>
Amortisations	2.409.930	2.627.606
Net provisions	-1.193.073	447.736
Losses from receivables	362.182	207.520
<b>Other operating expenses</b>	<b>22.370.157</b>	<b>19.487.931</b>
Expenses on external services	18.374.364	16.831.594
Expenses with other taxes, charges and assimilated payments	2.248.613	1.840.782
Other expenses	1.747.180	815.555
<b>OPERATING EXPENSES - TOTAL</b>	<b>748.336.052</b>	<b>733.918.239</b>
<b>OPERATING RESULT</b>	<b>14.869.606</b>	<b>13.097.914</b>
<b>Financial income</b>	<b>2.078.220</b>	<b>1.402.921</b>
Interest income	1.252.018	1.190.017
Income from exchange rate differences	217.575	37.121
Income from dividends	74.370	63.745
Advance payment discounts	280.981	112.038
Other financial income		
Other financial revenues share of the loss from investments accounted for using the equity method	253.276	0
<b>Financial expenses</b>	<b>602.076</b>	<b>406.565</b>
Expenses regarding interests leasing	0	0
Operational leasing interests	48.117	104.295
Expenses due to exchange rate differences	553.959	192.439
Discounts received in advance	0	0
Other financial expenses	0	0
Other financial expenses - share of the loss from investments accounted for using the equity method	0	109.831
<b>FINANCIAL RESULT</b>	<b>1.476.144</b>	<b>996.356</b>
<b>TOTAL INCOME</b>	<b>765.283.879</b>	<b>748.419.073</b>

<b>TOTAL EXPENSES</b>	<b>748.938.129</b>	<b>734.324.803</b>
<b>GROSS RESULT</b>	<b>16.345.750</b>	<b>14.094.270</b>
Profit tax	7.623.716	7.132.084
<b>TOTAL NET PROFIT of which distributable</b>	<b>8.722.033</b>	<b>6.962.186</b>
Shareholders of the company	<b>8.722.033</b>	<b>6.962.186</b>
Minority interest		
<b>Other elements of comprehensive income</b>		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
<b>COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which at</b>	<b>8.722.033</b>	<b>6.962.186</b>
Shareholders of the company	<b>8.722.033</b>	<b>6.962.186</b>
Minority interest		
Earnings per share (in Lei)		
- basic	0,0913	0,0729
- diluted	0,0913	0,0729

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

	31.12.2025	31.12.2024
<b>ASSETS</b>		
<b>Fixed assets</b>	<b>52.002.592</b>	<b>48.321.257</b>
Tangible assets	30.976.346	27.403.592
Real estate investments	17.778.729	17.795.204
Assets related to the rights of use of leased assets	710.173	848.414
Software licences	810.973	680.066
Pharmacy licences	1.511.375	1.511.375
Participations held in group companies	0	0
Participations held in companies outside the group	130.286	5.916
Investments in jointly controlled entities accounted for using the equity method	0	0
Deposits and guarantees paid	84.710	76.692
<b>Current assets</b>	<b>332.406.386</b>	<b>327.453.347</b>
Stocks	63.507.955	57.207.397
Trade receivables	203.884.226	216.946.218
Other receivables	6.969.440	5.644.031
Cash and cash equivalents	58.044.765	47.655.701
<b>Accrued expenses</b>	<b>269.736</b>	<b>348.541</b>
<b>TOTAL ASSETS</b>	<b>384.678.715</b>	<b>376.123.145</b>
<b>EQUITIES AND DEBTS</b>		
<b>Equities</b>	<b>80.991.201</b>	<b>75.029.276</b>
Share capital	9.860.311	9.860.311
Share premiums	757.485	757.485
Reserves	45.052.644	41.040.587
Current result	8.722.033	6.962.186
Retained earnings	18.934.192	17.932.635
Retained earnings - retreatment	-911.629	-911.629
Profit distribution	0	0
Own shares	-1.316.108	-480.532
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-131.766
<b>Long-term debts</b>	<b>5.437.131</b>	<b>5.198.036</b>
Debts from long term operational leasing	416.662	534.563
Provisions		
Debts with deferred income tax	5.020.469	4.663.474
<b>Current debts</b>	<b>298.250.383</b>	<b>295.895.833</b>
Bank loans		
Debts from financial leasing		
Debts from operational leasing	333.866	347.431
Suppliers and other similar debts	292.788.848	290.910.220
Provisions	217.307	217.307

Current tax debts	1.976.492	1.893.262
Other short-term debts	2.933.869	2.527.612
<b>Total debts</b>	<b>303.687.514</b>	<b>301.093.870</b>
<b>TOTAL EQUITIES AND DEBTS</b>	<b>384.678.715</b>	<b>376.123.145</b>

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
 "TARUS" - Valentin Norbert TARUS e.U.

by representative  
 Valentin – Norbert TARUS

# Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2025

---

## NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25<sup>th</sup> 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13<sup>th</sup> 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1<sup>st</sup> 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1<sup>st</sup> 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In this context, **on 31.12.2025** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

In **January 2025**, Farmaceutica REMEDIA acquired 24% of the share capital of Novoengrama SRL, a medical recovery company operating in Cluj Napoca.

In **April 2025**, Farmaceutica REMEDIA Distribution & Logistics SRL (FRDL) closed its logistics warehouse in Pitești as a measure to streamline its operating costs.

In **September 2025**, Farmaceutica REMEDIA completed a share buyback operation carried out with the aim of implementing a Stock Option Plan. The number of shares repurchased on 23.09.2025, as part of the Public Tender Offer approved by the ASF through Decision 841/28.08.2025 and Amendment 888/11.09.2025, is 954.808 shares, representing 1% of the share capital. The total amount paid by Farmaceutica REMEDIA was 811,586.80 Lei, with a repurchase price of 0.85 Lei per share.

In **November 2025**, in order to streamline operating costs in the pharmacy business line, transferred in 2024 to Farmaceutica REMEDIA Distribution & Logistics SRL, the rural pharmacies in Mohu (Sibiu County) and Toplița (Hunedoara County) and Drogheria Horea in Deva were closed.

During 2025 Farmaceutica REMEDIA S.A. did not participate in mergers.

# Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2025

---

## **NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS**

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counterperformance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting
- Retreatment of operational leasing contracts according to IFRS 16

The company holds participations in other companies, in one of them having the control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

The companies whose financial statements are consolidated are:

- Farmaceutica REMEDIA S.A.
- Farmaceutica REMEDIA Distribution & Logistics S.R.L.

## Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2025

- PHARMA EXPERTSPEDITION SRL - Farmaceutica REMEDIA S.A. holds 50% of the share capital, using the equity method

Starting with 2012, for the class of tangible assets «Lands and buildings», the Company passed from the cost-based accounting model to the reassessment model.

The financial statements as at 31.12.2025 have been prepared in accordance with International Financial Reporting Standards (IFRS).

Regarding the association with PHARMA EXPERTSPEDITION SRL, based on the investment agreement dated 16.12.2021, considering that decisions are taken unanimously by the two partners who each hold 50% of the shares, it is presumed that the entity PHARMA EXPERTSPEDITION SRL is jointly controlled in accordance with the requirements of IFRS 11, it is an entity of the association type with legal personality jointly controlled - IFRS 11.

Therefore the investment in this entity will be accounted for using the "equity method" in accordance with IFRS 11 and IAS 28.

**The preliminary consolidated financial statements on 31.12.2025 were not audited by the independent financial auditor.**

### NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2025 – 31.12.2025, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2025 (Lei)	Realisations Jan-Dec 2024 (Lei)	Evolution 2025/2024 (%)
1.	Net sales of goods *	752.452.265	737.609.125	2,01%
2.	Other operating revenues	10.753.394	9.407.028	14,31%
3.	Total operating revenues	763.205.659	747.016.152	2,17%
4.	Total operating costs *	748.336.052	733.918.239	1,96%
5.	Operating result	14.869.606	13.097.914	13,53%
6.	Financial result	1.476.144	996.356	48,15%
7.	Gross result	16.345.750	14.094.270	15,97%

\* Including trade discounts granted/received

**"Other operating revenues"** mainly comprise the following categories of revenues:

- rents
- services (logistics, registration, marketing)
- BD Rowa services
- sale of assets
- other services

Farmaceutica REMEDIA S.A. – Consolidated financial  
statements concluded on 31.12.2025

- real estate investment income
- other operating revenue

**NOTE 4 ECONOMIC-FINANCIAL INDICATORS**

<b>LIQUIDITY AND WORKING CAPITAL</b>	<b>FR</b>	<b>FRDL</b>
<b>Current liquidity (Current assets / Current debts)</b>	6,77	1,06
Current assets	21.287.846	312.279.811
Current debts	3.146.744	295.937.164
<b>Degree of indebtedness (Borrowed capital / Equity x 100)</b>	<b>0,00%</b>	<b>0,00%</b>
Borrowed capital	0	0
Equity	59.998.974	21.632.780
<b>Turnover speed for client debit items (Average customer balance / turnover *365)</b>	<b>88 days</b>	<b>97 days</b>
Average customer balance	3.570.517	199.860.554
Net turnover	14.843.465	749.889.588
<b>Turnover speed of stocks (average stock/ net COGS)*365</b>	<b>71 days</b>	<b>30 days</b>
Average stock	1.414.583	56.676.624
COGS net	7.283.491	691.245.167

\* including financial leasing

**Notes:**

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of these companies there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances.

4) The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin-Norbert TARUS

**NOTE 5 Reporting on activity segments  
Consolidated**

		Hospitals & Clinics	Distribution	REMEDIA Pharmacies E-commerce	Services provided and rents	BD ROWA Robots	TOTAL * 2025
<b>Net turnover</b>		<b>234.904.016</b>	<b>500.474.842</b>	<b>10.270.578</b>	<b>6.627.287</b>	<b>7.480.848</b>	<b>759.757.571</b>
	Income from the sale of goods	234.904.016	503.232.364	10.270.578	0	6.802.827	<b>755.209.785</b>
	Commercial discounts granted	0	2.757.522	0	0		<b>-2.757.522</b>
	Income from services provided and rents			0	6.627.287	678.021	<b>7.305.308</b>
<b>Other operating income</b>		0	788.328	0	2.659.757		<b>3.448.086</b>
<b>OPERATING INCOME - TOTAL</b>		<b>234.904.016</b>	<b>501.263.170</b>	<b>10.270.578</b>	<b>9.287.044</b>	<b>7.480.848</b>	<b>763.205.659</b>
<b>Expenses with goods</b>		<b>226.343.385</b>	<b>456.788.188</b>	<b>8.372.981</b>	<b>0</b>	<b>5.128.363</b>	<b>696.632.918</b>
	Expenses regarding goods	240.238.446	464.069.632	8.372.981		5.128.363	<b>717.809.422</b>
	Commercial discounts received	-13.895.061	-7.281.444	0	0		<b>-21.176.505</b>
<b>Gross margin from sales of goods</b>		<b>8.560.631</b>	<b>44.474.982</b>	<b>1.897.597</b>	<b>9.287.044</b>	<b>1.674.464</b>	<b>66.572.741</b>
							<b>0</b>
<b>Other operating costs</b>		<b>5.635.807</b>	<b>37.784.220</b>	<b>3.881.294</b>	<b>2.690.704</b>	<b>1.711.109</b>	<b>51.703.134</b>
	Direct costs	4.238.766	26.567.307	3.320.749	1.504.738	1.247.755	<b>36.879.314</b>
	Logistics costs	626.467	5.773.249	0			<b>6.399.716</b>
	Indirect costs	770.575	5.443.663	560.545	1.185.966	463.354	<b>8.424.104</b>
<b>OPERATING EXPENSES - TOTAL</b>		<b>231.979.193</b>	<b>494.572.408</b>	<b>12.254.275</b>	<b>2.690.704</b>	<b>6.839.472</b>	<b>748.336.053</b>
							<b>0</b>
<b>Operating result</b>		<b>2.924.823</b>	<b>6.690.762</b>	<b>-1.983.696</b>	<b>6.596.340</b>	<b>641.376</b>	<b>14.869.606</b>
<b>Financial result</b>							<b>1.476.145</b>
<b>Gross result</b>							<b>16.345.750</b>
	Profit tax						<b>-7.623.716</b>
<b>Net profit</b>							<b>8.722.033</b>

**NOTE 6 CAPITALS CHANGES**

Consolidated

	Share	Legal	Revaluation	Other	Share	Retained	Current	Own	TOTAL
	capital	reserves	reserves	reserves	premiums	earnings	result	shares	2025
<b>Balance on 01.01.2025</b>	<b>9.860.311</b>	<b>2.122.356</b>	<b>25.404.128</b>	<b>13.514.103</b>	<b>757.485</b>	<b>17.021.006</b>	<b>6.962.186</b>	<b>-612.298</b>	<b>75.029.276</b>
Restoration of profit account retreatments 2024						-5.616.612	5.616.612		0
Profit transfer 2024 (FR) to retained earnings						5.876.151	-5.876.151		0
Profit distribution 2024(FR) to dividends				0		-3.786.328			-3.786.328
Profit distribution 2024(FR) to other reserves				2.089.823		-2.089.823			0
Account closure 129									0
Profit transfer 2024(FRDL) to retained earnings						6.702.647	-6.702.647		0
Profit distribution 2024(FRDL) to dividends						-3.500.000			-3.500.000
Profit distribution 2024(FRDL) to other reserves				0					0
Accounting result 2025FR + FRDL							12.143.475		12.143.475
Profit account retreatment						3.421.441	-3.421.441		0
Buildings + lands outputs			-424.189						-424.189
Revaluation of buildings and lands			2.267.900						2.267.900
Transfer reserves from funds				0					0
Reported results - retreating						32.433			32.433
Buy own shares								-811.537	-811.537
Deferred tax									0
Retreatment of operational leasing (IFRS 16)						-38.353			-38.353
Investments in jointly controlled entities									0
Losses from the free transfer of own shares								0	0
Reserves – employee share plan (IFRS 2)				78.524					78.524
<b>Balance on 31.12.2025</b>	<b>9.860.311</b>	<b>2.122.356</b>	<b>27.247.838</b>	<b>15.682.450</b>	<b>757.485</b>	<b>18.022.563</b>	<b>8.722.033</b>	<b>-1.423.835</b>	<b>80.991.201</b>

Farmaceutica REMEDIA S.A. – Consolidated financial  
statements concluded on 31.12.2025

**NOTE 7 TREASURY FLOWS STATEMENT (RON)  
Consolidated**

<b>Cash flows from operating activities</b>	<b>12/31/2025</b>
Collections from the sale of goods and from the provision of services	847.466.642
Other cash inflows	23.898.394
Payments to suppliers of goods and services	-791.808.619
Payments to and on behalf of employees (incl. taxes on salaries)	-23.141.633
Corporate tax payments	-7.297.880
Payments to other taxes and fees	-33.662.135
Paid interests	0
Collected interests (current account)	1.198.892
Other cash outflows	-1.005.035
<b>Total operating cash flow</b>	<b>15.648.626</b>
<b>Cash flow from investment activities</b>	<b>0</b>
Proceeds from the sale of long-term assets and financial investments	111.727
Collected interests (from deposits)	47.917
Collected dividends	74.370
Payments for the purchase of long-term assets	-1.326.447
<b>Total cash flow from investments</b>	<b>-1.092.433</b>
<b>Cash flow from financing activities</b>	<b>-4.167.129</b>
Short-term loan withdrawals	0
Repayment of short-term loans	0
Net foreign exchange differences	-249.542
Funding received from shareholders	0
Repayments of long-term loans, including interest	0
Payments to shareholders (dividends)	-3.350.000
Payments of own shares	-567.587
Loans granted between subsidiaries	
<b>Total cash flow from financing</b>	<b>-4.167.129</b>
<b>Total cash flow</b>	<b>10.389.064</b>
<b>Cash at the beginning of the period</b>	<b>47.655.701</b>
Cash at the beginning period of the associat	
<b>Cash at the end of the period</b>	<b>58.044.765</b>

**Farmaceutica REMEDIA S.A.**

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin-Norbert TARUS



## **PRELIMINARY 2025 UNCONSOLIDATED REPORT**

**Board of Administrators of  
Farmaceutica REMEDIA S.A.**

### **Farmaceutica REMEDIA S.A.**

Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197

Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640  
remedia@remedia.ro, www.remedia.ro

Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082

IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest

IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

**PRELIMINARY 2025 REPORT - unconsolidated**  
**According to F.S.A. Regulation No. 5/2018**  
Date of the report: 25.02.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**  
Paid-up share capital: **9.548.082 Lei**  
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd., pc  
330160**  
Tel./fax.: **+40 254 223 260, +40 254 226 197**  
No. and date of registration  
with the Trade Register Office: **J20/700/25.07.1991**  
Tax registration number: **RO2115198**

Securities: **RMAH shares**  
**(Registration certificate No. AC-1470-7/17.06.2021)**  
Type: **Common Nominative**  
Date of registration: **17.03.1997**  
Nominal value: **0,10 Lei**  
Position in RNSC Register: **1636**  
Total number: **95.480.820**  
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010,70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	<b>TOTAL</b>	<b>95.480.820</b>	<b>9.548.082,00 Lei</b>

Organised market on which securities are traded:

**Bucharest Stock Exchange – Standard category**

The total market value on 25.02.2026 is of 85.932.738 Lei, at a value of a 0,90 Lei/RMAH share

## 1. Important events to report

In **January 2025**, Farmaceutica REMEDIA acquired 24% of the share capital of Novoengrama SRL, a medical recovery company operating in Cluj Napoca.

In **September 2025**, Farmaceutica REMEDIA completed a share buyback operation carried out with the aim of implementing a Stock Option Plan. The number of shares repurchased on 23.09.2025, as part of the Public Tender Offer approved by the ASF through Decision 841/28.08.2025 and Amendment 888/11.09.2025, is 954.808 shares, representing 1% of the share capital. The total amount paid by Farmaceutica REMEDIA was 811,586.80 Lei, with a repurchase price of 0,85 Lei per share.

## 2. The general description of the financial position and of the issuer's performances and of its branches related to 2025

During the period 01.01.2025 - 31.12.2025 the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2025 (Lei)	Realisations Jan-Dec 2024 (Lei)	Evolution 2025/2024 (%)
1.	Net sales of goods *	9.288.883	9.112.606	1,93%
2.	Other operating revenues	8.214.340	8.888.455	-7,58%
3.	Total operating revenues	17.503.223	18.001.061	-2,77%
4.	Total operating costs *	14.566.659	18.461.880	-21,10%
5.	Operating result	2.936.563	-460.818	737,25%
6.	Financial result	4.111.784	6.336.969	-35,11%
7.	Gross result (profit)	7.048.348	5.876.151	19,95%

\* Including commercial discounts granted/received

**"Other operating revenues"** mainly comprise the following categories of revenues:

- rents – 59% out of "Other operating revenues"
- BD Rowa services – 8% out of "Other operating revenues"
- sales of assets – 20% out of "Other operating revenues"
- real estate investments - 12% out of "Other operating revenues"
- other services – 1% out of "Other operating revenues"

## 3. The financial statements as at 31.12.2025 were not audited by the independent financial auditor.

#### 4. Economic-Financial Indicators

<b>LIQUIDITY AND WORKING CAPITAL</b>	<b>31.12.2025</b>
<b>Current liquidity (Current assets / Current debts)</b>	6,77
Current assets	21.287.846
Current debts	3.146.744
<b>Degree of indebtedness (Borrowed capital / Equity x 100)</b>	<b>0,00%</b>
Borrowed capital	0
Equity	59.998.974
<b>Turnover speed for client debit items (Average customer balance /turnover *365)</b>	<b>88 days</b>
Average customer balance	3.570.517
Net turnover	14.843.465
<b>Turnover speed of stocks (average stock balance/cogs)*365</b>	<b>71 days</b>
Average stock balance	1.414.583
Net COGS	7.283.491

**Notes:**

- 1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.
- 2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.
- 3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 88 days is a normal one under the circumstances.
- 4) The value of the **No. of Storage Days** indicator, can be considered as falling within the specifics of the activity, increase in the indicator being caused by the decrease in the number of pharmaceutical units.

Chairman of the Board of Administrators  
"TARUS" Valentin Norbert TARUS e.U.

by representative  
Valentin-Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - unconsolidated (Lei)

	31.12.2025	31.12.2024
<b>Net turnover</b>	<b>14.843.465</b>	<b>14.077.445</b>
Income from the sale of goods	9.288.883	9.112.606
Commercial discounts granted	0	0
Income from services provided and rents	5.554.582	4.964.839
<b>Other operating income</b>	<b>2.659.758</b>	<b>3.923.616</b>
<b>OPERATING INCOME - TOTAL</b>	<b>17.503.223</b>	<b>18.001.061</b>
<b>Expenses with materials</b>	<b>7.699.017</b>	<b>8.224.928</b>
Expenses regarding goods	7.283.491	7.641.695
Commercial discounts received	0	-3.913
Expenses with raw materials and consumables	252.723	367.447
Other expenses with materials (inventory objects)	27.245	33.942
Energy and water expenses	135.557	185.757
<b>Expenses with personnel</b>	<b>2.542.631</b>	<b>5.939.976</b>
Salaries and allowances	1.905.267	3.377.704
Expenses with insurance and social protection	80.271	159.170
Other personnel expenses	557.093	2.403.102
<b>Amortisations and provisions</b>	<b>1.402.672</b>	<b>1.686.445</b>
Amortisations	1.402.402	1.686.312
Net provisions	0	0
Losses from receivables	270	133
<b>Other operating expenses</b>	<b>2.922.340</b>	<b>2.610.531</b>
Expenses on external services	1.566.267	1.522.130
Expenses with other taxes, charges and assimilated payments	690.693	766.540
Other expenses	665.380	321.861
<b>OPERATING EXPENSES - TOTAL</b>	<b>14.566.659</b>	<b>18.461.880</b>
<b>OPERATING RESULT</b>	<b>2.936.563</b>	<b>-460.818</b>
<b>Financial income</b>	<b>4.214.431</b>	<b>6.387.436</b>
Interest income	627.655	323.308
Income from exchange rate differences	12.406	382
Income from dividends	3.574.370	6.063.745
Advance payment discounts	0	0
Other financial income	0	0
<b>Financial expenses</b>	<b>102.647</b>	<b>50.467</b>
Interest expense		0
Operational leasing interest	2.348	42.122
Expenses from exchange rate differences	100.299	8.345
Discounts collected in advance		0
Other financial expenses		
<b>FINANCIAL RESULT</b>	<b>4.111.784</b>	<b>6.336.969</b>
<b>TOTAL INCOME</b>	<b>21.717.654</b>	<b>24.388.497</b>
<b>TOTAL EXPENSES</b>	<b>14.669.306</b>	<b>18.512.346</b>

<b>GROSS RESULT</b>	<b>7.048.348</b>	<b>5.876.151</b>
Profit tax	460.920	0
<b>TOTAL NET PROFIT of which distributable</b>	<b>6.587.427</b>	<b>5.876.151</b>
Shareholders of the company	<b>6.587.427</b>	<b>5.876.151</b>
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
<b>COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which distributable</b>	<b>6.587.427</b>	<b>5.876.151</b>
Shareholders of the company	<b>6.587.427</b>	<b>5.876.151</b>
Minority interest		
Earnings per share (in Lei)		
- basic	0,0690	0,0615
- diluted	0,0690	0,0615

Chairman of the Board of Administrators  
 "TARUS" - Valentin Norbert TARUS e.U.

by representative  
 Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - unconsolidated (Lei)

	31.12.2025	31.12.2024
<b>ASSETS</b>		
<b>Fixed assets</b>	<b>46.787.279</b>	<b>50.111.863</b>
Tangible assets	28.069.841	26.548.361
Real estate investments	17.778.729	17.795.204
Operational leasing assets	28.477	32.073
Software licences	130.449	80.812
Pharmacy licences	0	0
Participations held in group companies	602.200	602.200
Participations held in companies outside the group	130.286	5.916
Deposits and guarantees paid	47.297	5.047.297
<b>Current assets</b>	<b>21.287.846</b>	<b>12.956.220</b>
Stocks	930.918	817.278
Trade receivables	4.503.448	1.636.868
Other receivables	278.189	598.653
Cash and cash equivalents	15.575.290	9.903.422
<b>Accrued expenses</b>	<b>115.420</b>	<b>195.037</b>
<b>TOTAL ASSETS</b>	<b>68.190.545</b>	<b>63.263.121</b>
<b>EQUITIES AND DEBTS</b>		
<b>Equities</b>	<b>59.998.974</b>	<b>56.087.178</b>
Share capital	9.860.311	9.860.311
Share premiums	757.485	757.485
Reserves	44.518.694	40.506.637
Current result	6.587.427	5.876.151
Retained earnings	11.122	11.122
Retained earnings - retreatment	-312.229	-312.229
Profit distribution	0	0
Own shares	-1.316.108	-480.532
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-131.766
<b>Long-term debts</b>	<b>5.044.827</b>	<b>4.693.953</b>
Debts from long term operational leasing	24.358	30.479
Debts from long term leasing		
Provisions		
Debts with deferred income tax	5.020.469	4.663.474
	<b>3.146.744</b>	<b>2.481.990</b>
<b>Current debts</b>		
Bank loans		
Debts from operational leasing	6.121	2.740
Suppliers and other similar debts	1.864.818	1.528.062
Provisions		
Current tax debts	77.341	

Other short-term debts	1.198.464	951.188
<b>Total debts</b>	<b>8.191.571</b>	<b>7.175.943</b>
<b>TOTAL EQUITIES AND DEBTS</b>	<b>68.190.545</b>	<b>63.263.121</b>

Chairman of the Board of Administrators  
 "TARUS" - Valentin Norbert TARUS e.U.

by representative  
 Valentin – Norbert TARUS

# Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2025

---

## NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25<sup>th</sup> 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13<sup>th</sup> 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1<sup>st</sup> 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1<sup>st</sup> 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In this context, on **31.12.2025** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

In **January 2025**, Farmaceutica REMEDIA acquired 24% of the share capital of Novoengrama SRL, a medical recovery company operating in Cluj Napoca.

In **September 2025**, Farmaceutica REMEDIA completed a share buyback operation carried out with the aim of implementing a Stock Option Plan. The number of shares repurchased on 23.09.2025, as part of the Public Tender Offer approved by the ASF through Decision 841/28.08.2025 and Amendment 888/11.09.2025, is 954.808 shares, representing 1% of the share capital. The total amount paid by Farmaceutica REMEDIA was 811,586.80 Lei, with a repurchase price of 0.85 Lei per share.

During 2025 Farmaceutica REMEDIA S.A. did not participate in mergers.

## NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

## Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2025

---

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counterperformance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting

Starting with 2012, for the class of tangible assets «Lands and buildings», the Company passed from the cost-based accounting model to the reassessment model.

The financial statements as at 31.12.2025 have been prepared in accordance with International Financial Reporting Standards (IFRS).

**The preliminary unconsolidated financial statements on 31.12.2025 were not audited by the independent financial auditor.**

### **NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES**

During the period 01.01.2025 – 31.12.2025, the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Farmaceutica REMEDIA S.A. – Unconsolidated financial  
statements concluded on 31.12.2025

Crt. No.	Indicator	Realisations Jan-Dec 2025 (Lei)	Realisations Jan-Dec 2024 (Lei)	Evolution 2025/2024 (%)
1.	Net sales of goods *	9.288.883	9.112.606	1,93%
2.	Other operating revenues	8.214.340	8.888.455	-7,58%
3.	Total operating revenues	17.503.223	18.001.061	-2,77%
4.	Total operating costs *	14.566.659	18.461.880	-21,10%
5.	Operating result	2.936.563	-460.818	737,25%
6.	Financial result	4.111.784	6.336.969	-35,11%
7.	Gross result	7.048.348	5.876.151	19,95%

\* Including trade discounts granted/received

“Other operating revenues” mainly comprise the following categories of revenues:

- rents – 59% out of “Other operating revenues”
- BD Rowa services – 8% out of “Other operating revenues”
- sales of assets – 20% out of “Other operating revenues”
- real estate investments - 12% out of “Other operating revenues”
- other services – 1% out of “Other operating revenues”

**NOTE 4 ECONOMIC-FINANCIAL INDICATORS**

<b>LIQUIDITY AND WORKING CAPITAL</b>	<b>31.12.2025</b>
<b>Current liquidity (Current assets / Current debts)</b>	6,77
Current assets	21.287.846
Current debts	3.146.744
<b>Degree of indebtedness (Borrowed capital / Equity x 100)</b>	<b>0,00%</b>
Borrowed capital	0
Equity	59.998.974
<b>Turnover speed for client debit items (Average customer balance /turnover *365)</b>	<b>88 days</b>
Average customer balance	3.570.517
Net turnover	14.843.465
<b>Turnover speed of stocks (average stock/ net COGS)*365)</b>	<b>71 days</b>
Average stock	1.414.583

## Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2025

---

COGS net	7.283.491
----------	-----------

### **Notes:**

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 88 days is a normal one under the circumstances.

4) The value of the **No. of Storage Days** indicator, can be considered as falling within the specifics of the activity, increase in the indicator being caused by the decrease in the number of pharmaceutical units.

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin-Norbert TARUS

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2025

**NOTE 5 Reporting on activity segments  
Unconsolidated**

		Remedia		Rents for	Provided	TOTAL *
		farmacies	BD ROWA/Robots	spaces/auto	services	2025
<b>Net turnover</b>		<b>699.822</b>	<b>9.267.081</b>	<b>4.875.681</b>	<b>880</b>	<b>14.843.464</b>
	Income from the sale of goods	699.822	8.589.060			<b>9.288.882</b>
	Commercial discounts granted	0		0	0	<b>0</b>
	Income from services provided and rents	0	678.021	4.875.681	880	<b>5.554.582</b>
<b>Other operating revenues</b>		<b>0</b>			2.659.758	<b>2.659.758</b>
<b>OPERATING REVENUES - TOTAL</b>		<b>699.822</b>	<b>9.267.081</b>	<b>4.875.681</b>	<b>2.660.638</b>	<b>17.503.222</b>
						<b>0</b>
<b>Expenses with goods</b>		<b>579.670</b>	<b>6.703.821</b>	<b>0</b>	<b>0</b>	<b>7.283.491</b>
	Expenses regarding goods	579.670	6.703.821	0	0	<b>7.283.491</b>
	Commercial discounts received	0		0	0	<b>0</b>
<b>Gross margin from sales of goods</b>		<b>120.152</b>	<b>1.885.239</b>	<b>0</b>	<b>0</b>	<b>2.005.391</b>
						<b>0</b>
<b>Other operating costs</b>		<b>709.290</b>	<b>1.711.109</b>	<b>4.862.064</b>	<b>705</b>	<b>7.283.168</b>
	Direct costs	148.745	1.247.755	956.730	0	<b>2.353.230</b>
	Logistics costs	0		0	0	<b>0</b>
	Promotion costs	0		0	0	<b>0</b>
	Indirect costs	560.545	463.354	3.905.334	705	<b>4.929.938</b>
<b>OPERATING EXPENSES - TOTAL</b>		<b>1.288.960</b>	<b>8.414.930</b>	<b>4.862.064</b>	<b>705</b>	<b>14.566.659</b>
						<b>0</b>
<b>Operating result</b>		<b>-589.138</b>	<b>852.151</b>	<b>13.617</b>	<b>2.659.933</b>	<b>2.936.563</b>
<b>Financial result</b>						<b>4.111.784</b>
<b>Gross result</b>						<b>7.048.347</b>
	Profit tax					460.920
<b>Net profit</b>						<b>6.587.427</b>

## Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2025

### NOTE 6 CAPITALS CHANGE Unconsolidated

	Share	Legal	Revaluation	Other	Share	Retained	Current	Own	TOTAL
	capital	reserves	reserves	reserves	premiums	earnings	result	shares	2025
<b>Balance on 01.01.2025</b>	<b>9.860.311</b>	<b>2.121.796</b>	<b>25.404.128</b>	<b>12.980.713</b>	<b>757.485</b>	<b>-301.106</b>	<b>5.876.151</b>	<b>-612.298</b>	<b>56.087.178</b>
									<b>0</b>
Profit transfer 2024 to retained earnings						5.876.151	-5.876.151		<b>0</b>
Profit distribution 2024 to dividends				0		-3.786.328			<b>-3.786.328</b>
Profit distribution 2024 to other reserves				2.089.823		-2.089.823			<b>0</b>
Profit distribution 2024 to other reserves									<b>0</b>
Result 2025							6.587.427		<b>6.587.427</b>
Legal reserve 2024									<b>0</b>
Account closure 129									<b>0</b>
Buildings + lands outputs			-424.189						<b>-424.189</b>
Revaluation of buildings and lands			2.267.900						<b>2.267.900</b>
Deferred tax									<b>0</b>
Transfer reserves from funds				0		0			<b>0</b>
Buy own shares								-811.537	<b>-811.537</b>
Losses from the free transfer of own shares								0	<b>0</b>
Reserves – employee share plan (IFRS 2)				78.522					<b>78.522</b>
<b>Balance on 31.12.2025</b>	<b>9.860.311</b>	<b>2.121.796</b>	<b>27.247.837</b>	<b>15.149.058</b>	<b>757.485</b>	<b>-301.106</b>	<b>6.587.427</b>	<b>-1.423.835</b>	<b>59.998.974</b>

Farmaceutica REMEDIA S.A. – Unconsolidated financial  
statements concluded on 31.12.2025

**NOTE 7 TREASURY FLOWS STATEMENT (RON)**

**Unconsolidated**

	<b>12/31/2025</b>
<b>Cash flows from operating activities</b>	
Collections from the sale of goods and from the provision of services	17.108.789
Other cash inflows	379.686
Payments to suppliers of goods and services	-11.628.752
Payments to and on behalf of employees (incl. taxes on salaries)	-2.089.947
Corporate tax payments	-140.973
Payments to other taxes and fees	-3.052.530
Paid interests	
Collected interests (current account)	627.655
Other cash outflows	-157.296
<b>Total operating cash flow</b>	<b>1.046.632</b>
<b>Cash flow from investment activities</b>	
Proceeds from the sale of long-term assets and financial investments	0
Collected interests (from deposits)	
Collected dividends	3.574.370
Payments for the purchase of long-term assets	
<b>Total cash flow from investments</b>	<b>3.574.370</b>
<b>Cash flow from financing activities</b>	
Short-term loan withdrawals	
Repayment of short-term loans	5.000.000
Net foreign exchange differences	-31.547
Funding received/granted	
Repayments of long-term loans, including interest	
Payments to shareholders (dividends)	-3.350.000
Payments of own shares	-567.587
Loans granted between subsidiaries	
<b>Total cash flow from financing</b>	<b>1.050.866</b>
<b>Total cash flow</b>	<b>5.671.868</b>
<b>Cash at the beginning of the period</b>	<b>9.903.422</b>
<b>Cash at the end of the period</b>	<b>15.575.290</b>

**Farmaceutica REMEDIA S.A.**

Chairman of the Board of Administrators

“TARUS” - Valentin Norbert TARUS e.U.

by representative

Valentin-Norbert TARUS